casestudy写作-Aurobindo制药公司案例研究

《casestudy写作-Aurobindo制药公司案例研究》由会员分享，可在线阅读，更多相关《casestudy写作-Aurobindo制药公司案例研究（5页珍藏版）》请在装配图网上搜索。

1、 专业留学生网课代修辅导中心 为留学生提供高效、优质的网课代修服务 case study 写作-Aurobindo 制药公司案例研究 A -On Aurob indo Pharma Global strategy for In dia n pharmacy compa nies and the opport un ity in emerg ing markets: A case study on Aurob indo Pharma Focus Aim: To un dersta nd the trends in In dia n pharmacy compa nies which have b

2、ee n rece ntly going global by investing abroad with an intention for market expansion? 网课代修 Objectives: To find out the stre ngths of the In dia n Pharmaceutical In dustry and an alyse the patter n of Mergers and Acquisiti ons by various compa nies across the globe. To throw light on the strategies

3、 followed by Aurob indo Pharma in acquiri ng other pharma compa ni es. Co ntext The research includes strategy of the emerging pharmaceutical companies in India and un dersta nds the trends and process of the compa nies that have bee n going global to expa nd their market in the world-wide. Literatu

4、re review: In pharmaceutical sector around the world, In dia ranks 4th in terms of volume and 13th in terms of value. In the year 2006 the value was USD 7.42 billio n, the growth has been in creased by 12.9% over the previous year. In this total sales 90% of the sales are acco un ted as gen erics an

5、d the remaining are patented drugs. Now a day governments of various countries, patients and in dustries are pulli ng atte nti on towards gen eric drugs, due to lower in cost and less R&D in vestme nt tha n compares to that of the pate nted drugs. In the year 2005 the gen eric market has bee n in cr

6、eased by 20% in the world which is four times that of the pate nted drugs and three times that of the pharmaceuticals market. US market alone had acquired 44% of the gen eric drugs (Pharmabiz, 2009). The Compou nd Ann ual Growth Rate (CAGR) of gen eric drugs in In dia n pharmaceuticals has bee n in

7、creased by 16.6% duri ng the period of 2001-05. The expected CAGR during the period of 2009-14 would be 13.2% and approximately the total value may reach $15,490m in 2014 (Research and Markets, 2009). In the year 2009 in In dia there were more tha n 80 FDA approved pla nts, Italy (55) and Chi na (27

8、). The In dia n pharmaceuticals compa nies like Cipla, Dr. Reddy tab; Wockhardt, Lupin and Nicholas Piramal are doing well in developed market such as US and Europe. These compa nies have excit ing values in formulati on, bulk drugs, gen erics, novel drug delivery system, new chemical en tities, bio

9、tech no logy etc (Research and Markets, 2007) 专业留学生网课代修辅导中心 为留学生提供高效、优质的网课代修服务 4.1 In dia n pharmaceutical market structure: Source: Cygnus, 2007 According to Dr. Richard Gerster, “ TheIndian pharmaceutical industry is a success story providing employment for millions and ensuring that essential dru

10、gs at affordable prices are available to the vast populati on of this sub-c ontinen t.The In dia n pharmaceuticals ranks very high in terms of quality, tech no logy and the range of medici nes manu factured. In dia n pharmaceuticals market will grow 10-14%, to touch $40 billio n by 2015 (Mcki nsey,

11、2009). In dia has a powerful biotech no logy that can overthrow by the revoluti on of agriculture, healthcare, in dustrial process ing and environmen tal susta in ability .In In dia there are 100 research laboratories and more tha n 400 educati onal and trai ning in stitutes across the country (Phar

12、ma In dia, 2005). Major compa nies in In dia 2006 Source: compa ny annual report FY 2006-07, *a nnual report 2006 December ending. In the above figure y-axis in dicates to turno ver (Rs.b n) In dia n pharmaceuticals is divided into two ben efits, one is strong domestic con sumpti on growth and robus

13、t export opport un ities (In dus view, 2009). 4.2 Mergers and acquisiti ons of In dia n pharmaceutical compa nies The major reas on for acquisiti ons is to attai ning access to new tech no logies, clinical research, catapult ing the market share and platform for improvi ng custom syn thesis and work

14、 ing with new clie nts. The major compa nies acquiri ng acquisiti ons in In dia are Ran baxy, Dr. Reddy an and Wockhardt. Over the last decade the outsourcing has become the important part for the pharmaceutical companies. The main reason for the outsourcing is rising pressure to reduce costs, and t

15、ime-to-market, this leads to the in creas ing the tech ni cal dema nding areas such as drug discovery and biotech R&D. Outsourc ing opport un ities has bee n rapidly grow ing in the market like Easter n Europe, China, In dia. In dia n pharmaceutical in dustries are putt ing effort on the developme n

16、t of the product for global gen eric market and this will be visible with the DMF fili ng at the US FDA (DMFs are gen eric dossiers filed with the FDA in order to allow the API to appear in marketed drugs). 30% of the DMF fili ngs at US FDA are filed by In dia n compa nies. Dr. Reddy do, cipla, Ran

17、baxy, matrix and lup in are the leadi ng In dia n compa nies of DMFs filed in US. From the sources of US and European countries they made research on Indian based pharmaceuticals companies regarding merging and acquisitions and they were pleased to announce some name to the Indian companies and deci

18、ded to name as IndianPharmaceutical MNC. Mainly US and European countries have focused on Indian due to the vast change in research work done and the main plus points for them were the laws of In dia n gover nment have cha nged drastically like providing new opportunities to launch patented molecule

19、s this point made them interest in investing Indian pharmaceuticals, and likewise India pharma is becoming strong manu facturi ng sta nd and with low-cost developme nt, manu facturi ng dest in ati on. s, Disl s, aurobi 专业留学生网课代修辅导中心 为留学生提供高效、优质的网课代修服务 Source: Shiva ni Shukla, 2006. The global has be

20、e n rapidly cha nging into the gen eric market; here are some compa nies that have bee n in vested, acquired and deals in 2008-09. Gree n cross Pharma in Sin gapore was acquired by Asce nt; Pfizer pla nt in Irela nd was acquired by Hovione, PharmaPro manu facturi ng facility was acquired by URL Phar

21、ma, ECR pharmaceuticals was acquired by HI-Tech pharmacal. Source: Research and Markets, 2009. Indian pharmaceutical market in U.S., has been continuously increasing, a $440 billion market appoints 47% of the global pharmaceutical market. In February 2009, Indian pharmaceutical compa nies in cludi n

22、g large and mid-sized all together have assured approvals for 15 Abbreviated New Drug Applicatio ns (ANDAs) (In dus view, 2009). Strategies: In order to expa nd their market some compa nies have en tered into foreig n markets in gen eric drugs segme nt. Some compa nies have en tered directly by sett

23、 ing their own sales and market ing organisation, either in organic manner or through acquisitions and others have entered these market through partn ership or merging with well established compa ni es. Ran baxy acquired Ohm Laboratories in US in 1995, Jubila nt Orga no sys acquired Cadista pharmace

24、uticals (formerly Trige n Laboratories) an US gen eric compa ny in 2005. Aurob indo Pharma gained an FDA-complime nt formulati ons manu facturi ng pla nt in Dayt on, New Jersey in 2006, in the same year the company acquired Milpharm LTD in UK. Dr. Reddy sapproved as a MHRA manu facturi ng facilities

25、 in UK. Wockhardt has a manu facturi ng facility in UK, Irela nd and France (espicom, 2009). Aurob indo Pharma: Aurobindo was founded in the year 1986, by Mr P.V. Ramaprasad reddy, Mr. K. Nithyananda reddy and some highly committed group professionals. Aur obindo pharma launches Asia s largest formu

26、latio n facility in In dia in 2009. Visio n of the compa ny is “ To become Asias leadi ng and o among the top 15 gen eric Pharma compa nies in the world, by 2015 (aurob in do, 2009). R&D of the company lies in developing intellectual property in non-infringing processes and resolving complex chemist

27、ry challe nges. Aurob indo pharma expects to reach $2 billio n by the end of the year 2013, the compa ny lice nsing deal with Pfizer to sell gen erics drugs in more tha n 70 emerg ing compa nies and develop ing market in In dia (Fierce pharma, 2009). Aurob indo pharma is the first compa ny that make

28、s acquisiti on in Europe acquires Milpharm in UK in 2006, on agreement with the U.K. Whyte group LTD and Iracot LTD. This acquisition makes the compa ny to gai n immediate access to Europea n markets. This compa ny is profit maki ng compa ny in gen eric; it takes own ership over hun dred Marketi ng

29、Authorizati ons (MAs) Medici nes, and Health care products Regulatory Agency, UK (UK MHRA). Milpharm records 7.7 million in 12 mon ths of period ended 30th September 2005 (Aurobi ndo, 2006). Source: THE HINDU, journal, 2006 Source: PR Doma in News Release, 2006 专业留学生网课代修辅导中心 为留学生提供高效、优质的网课代修服务 The a

30、bove pie chart in dicates that Aurob indo pharma exports break-up in the year 2006 Research methodology Research the term fun dame ntally means expediti on for in formati on or data collectio n. It certainly means to accumulate the information regarding certain queries and to build up a convin ced s

31、cheme for that questi on. If there is no such a word like research all the scie ntific and social projects could be resulted in guess work and in exact data. The descriptive or relative, qualitative research work is typically prob ing, in concern it can either con tain some or all the criterio n men

32、 ti oned below. (Miles, 1994) Extremely inten sified and draw n out con tact in the field. Desig ned to atta in a holistic or complete picture. Little con siste nt in strume ntati on is used. Most an alysis is done with words. Take into acco unt the experie nces, opinions and feeli ngs of the partic

33、ipa nts. The research strategies gen erally used are the chose n case study and the groun ded theory. 5.1 Research paradigm A research paradigm is expa nded to the critical thinking of the stude nts that may help the stude nts to gain a clear view about the research with the differe nt examples. Pos

34、itivist paradigm is based on the philosophical idea which explores the social reality. Positivism paradigm has bee n in flue ncing the educati onal research for a long time, later half twen tieth it is criticized due to the lack in subjective states of in dividual. 5.2 Research approach There are fo

35、ur different types of research approaches, they are specification of a theory, design based on the theory, implementation, and evaluation. This research includes deductive and in ductive qua ntitative comes un der deductive and qualitative comes un der in ductive. Quan titative method mainly in clud

36、es objectively, cauti on and types of questi ons in this are pre-specified and outcome oriented. Qualitative mainly includes subjectively, meaning of the report. Types of questio ns are ope n-en ded and process orie nted. 5.3 Research method The research study is basically to understand the impact o

37、f pharmaceutical industries that have bee n going global to in crease their market. Thus, give n the research aim and objectives of the study, methodology that is employed for this study is basically to desk study rather going for primary survey method. The Aurob indo Pharma chose n for the case stu

38、dy is take n into acco unt with a view point and to review how the compa ny acquired and merged with other compa ni es. 5.4 Sampli ng procedure A sample is a finite part of statistical population, whose properties are studied to gain the in formati on of the whole (Webster, 1985). When it comes in c

39、ase of deali ng with people, it can be defi ned as a set of resp ondents picked out from a larger group for the reas on of survey. So as a part of sampli ng tech nique the questi onn aire is to be con ducted betwee n a selected group of actual clie nt and non clie nt households duri ng the course of

40、 the survey. 专业留学生网课代修辅导中心 为留学生提供高效、优质的网课代修服务 5.5 Method of data An alysis The published data collected on the pharmaceutical industry will be analysed with the help of diagrams, graphs and pie charts and draw con clusi ons based on the results obta in ed. Saun ders et al (2003) claims that there is

41、 no standard models to analyzing qualitative data but discuss one technique where the data are disaggregated into meaningful categories that are subsequently rearra nged and an alyzed for related data and key themes. Data collect ion Secon dary data collecti on The data is mostly collected from the

42、sec on dary form of publicati ons like articles, In dus view, In Pharma publishers, Cygnus bus in ess con sult ing and research, Pharmaceutical jour nal n ewspapers, Pharmabiz, market and research. Primary data collect ion Primary data is the collection of ideas all the way through the chain of vari

43、ous semi-structured con sultati ons con ducted by the researcher. This data can be collected by con duct ing in terviews and by daily writte n record of experie nces and observati ons. The research in cludes questi onn aire, case Ethical con siderati on Time pla n Week Number 1. Holiday 2. Read Lite

44、rature 3. Fi nalise Objectives 4. Draft Literature Review 5. Read Methodology Literature 6. Devise Research Approach 7. Draft Research Strategy and Method 8. Develop Questio nn aire 9. Pilot Test and Revise Questi onn aire 10. Adm ini ster Questi onn aire 11. En ter Data into Computer 12. An alyse Data 13. Update literature read 14. Complete remai ning chapters 15. Submit to tutor and await feedback 16. Pri nt, bind 17.Submit